Internal Medicine, Cardiovascular Disease · Omaha, NE
NPI
1053361824
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
339 N 78th St
Omaha, NE, 68114
Phone (402) 315-3788
Groups this clinician bills Medicare through
Medicare paid, 2024
$380K
4,527 services
Medicare patients, 2024
796
Average age 76
Drug cost, 2024
$1.2M
11,229 prescriptions
Company payments, 2025
$409
From 5 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marwan R Salfity was code 99214 (office e&m - established), 1,249 times for 691 patients. In total Marwan R Salfity billed 4,527 services in 31 codes, and Medicare paid $380K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-01-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,249 | 691 | $85.74 | $107K |
| J2785 Injection, regadenoson, 0.1 mg | Office | 780 | 194 | $5.71 | $4,450 |
| A9500 Technetium tc-99m sestamibi, diagnostic, per study dose | Office | 578 | 289 | $102.80 | $59K |
| 93306 Echocardiography (TTE/TEE) | Office | 499 | 471 | $138.14 | $69K |
| 78452 Myocardial Perfusion Scan | Office | 288 | 287 | $324.52 | $93K |
| 93015 Electrocardiogram | Office | 269 | 268 | $49.52 | $13K |
| 85610 Clinical Chemistry | Office | 157 | 16 | $4.20 | $659 |
| 93000 Electrocardiogram | Office | 132 | 108 | $9.64 | $1,272 |
| 99232 Hospital E&M - Subsequent | Facility | 122 | 21 | $61.96 | $7,559 |
| 36415 Venipuncture Blood Collection | Office | 92 | 78 | $4.90 | $451 |
| 99204 Office E&M - New | Office | 69 | 69 | $95.40 | $6,582 |
| 99213 Office E&M - Established | Office | 64 | 57 | $66.19 | $4,236 |
| 94621 Pulmonary Function Testing | Office | 58 | 58 | $111.69 | $6,478 |
| 93225 Electrocardiogram | Office | 36 | 36 | $10.37 | $373 |
| 93227 Electrocardiogram | Office | 34 | 34 | $12.61 | $429 |
By year: 2022 $627K for 6,122 services; 2023 $527K for 5,883 services; 2024 $380K for 4,527 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 157 | 16 | $4.20 | $659 |
| 36415 Venipuncture Blood Collection | 92 | 78 | $4.90 | $451 |
Medicare prescription drug claims, 2024
In 2024, the drug Marwan R Salfity prescribed most often to Medicare patients was Amlodipine Besylate, with 2,053 prescriptions and refills. In total Marwan R Salfity wrote 11,229 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 2,053 | 4,583 | 486 | $9,616 |
| Losartan Potassium Generic | 991 | 2,249 | 231 | $6,669 |
| Metoprolol Succinate Generic | 974 | 2,224 | 236 | $9,775 |
| Eliquis Apixaban | 844 | 1,289 | 145 | $747K |
| Doxazosin Mesylate Generic | 714 | 1,511 | 155 | $10K |
| Atorvastatin Calcium Generic | 612 | 1,601 | 160 | $4,851 |
| Carvedilol Generic | 558 | 1,242 | 128 | $3,060 |
| Amiodarone Hcl Generic | 434 | 814 | 101 | $4,522 |
| Furosemide Generic | 422 | 824 | 126 | $1,840 |
| Xarelto Rivaroxaban | 274 | 497 | 56 | $268K |
| Lisinopril Generic | 250 | 660 | 75 | $1,533 |
| Hydrochlorothiazide Generic | 233 | 555 | 50 | $906 |
| Clonidine Hcl Generic | 226 | 431 | 56 | $1,348 |
| Triamterene-Hydrochlorothiazid Triamterene/Hydrochlorothiazid | 183 | 393 | 47 | $1,000 |
| Potassium Chloride Generic | 177 | 418 | 47 | $2,784 |
Brand drugs: 1,412 claims; generic drugs: 9,817 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marwan R Salfity $409 ($409 in general payments such as food, travel and fees) from 5 companies. The largest payer was Heartflow, Inc. with $310.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.